-+ 0.00%
-+ 0.00%
-+ 0.00%

Leerink Partners Maintains Outperform on Benitec Biopharma, Raises Price Target to $18.27

Benzinga·11/16/2026 16:29:05
Listen to the news
Leerink Partners analyst Basma Radwan maintains Benitec Biopharma (NASDAQ:BNTC) with a Outperform and raises the price target from $18 to $18.27.